TP53 and cancer: Second, the healthy bone marrow controls had limited clinical annotation and may differ in age from the pediatric cancer cohorts; given that ribosome biogenesis and C-MYC/p53 networks are developmentally regulated, age mismatch could confound intergroup comparisons.